Speaker Profile
Ph.D., CEO, Atropos Health
Biography
Brigham Hyde brings over 15 years experience as an Investor, Operator, and Entrepreneur in Health Tech and Data. Prior to Atropos, he was President of Data and Analytics at Eversana, a life sciences commercialization service provider. At Symphony AI he led the investment in Concert AI in the oncology RWD space and held an operating role through the first 3 years of the company.He has served as President of Data Analytics at Eversana and Chief Data Officer at DRG (exited to Clarivate 2020). He is a founder and lead investor in Atropos Health, a Stanford RWD spinout, and holds advisory positions to multiple Data and Digital health tech ventures. Before beginning his career at Cowen and Company covering Genomics and Life Science Tools, Brigham received a Ph.D. in Clinical Pharmacology from Tufts University School of Medicine. He has held research faculty positions at Tufts University and MIT Media lab.
Session Abstract – PMWC 2026 Silicon Valley
Track Co-Chairs:
- William Oh, Yale Cancer Center
- David Reese, Amgen
Patient-centric data, such as Real-World Evidence (RWE) and Real-World Data (RWD), has become critical in reshaping drug development and healthcare decision-making. Over the last few years, regulatory agencies like the FDA and EMA have increasingly embraced RWE/RWD for decision-making processes, influencing everything from new drug indications to post-marketing surveillance. The integration of RWE and RWD is not only supporting clinical trial design and regulatory approvals, but also enabling precision medicine by providing deeper insights into patient subpopulations and their outcomes
Sessions:
- TBA
